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Background: Inhaled nitric oxide produces potent pulmonary vasodilation by acti-
vating soluble guanylate cyclase and increasing smooth muscle cell concentrations
of cyclic guanosine monophosphate. However, responses are often nonsustained,
and clinically significant increases in pulmonary vascular resistance have been noted
on its acute withdrawal. In vitro and in vivo data suggest that inhaled nitric oxide
decreases endogenous nitric oxide synthase activity. The effects of inhaled nitric
oxide on the downstream mediators of the nitric oxide/cyclic guanosine monophos-
phate cascade, soluble guanylate cyclase and phosphodiesterase 5, have not been
investigated. We sought to determine the effects of inhaled nitric oxide on endog-
enous cyclic guanosine monophosphate levels, soluble guanylate cyclase, and
phosphodiesterase 5 protein levels in the intact lamb.
Methods: Eleven 1-month-old lambs were mechanically ventilated. In 7 lambs,
inhaled nitric oxide (40 ppm) was administered for 24 hours and then acutely
withdrawn. Intermittent lung biopsy samples were obtained for cyclic guanosine
monophosphate concentrations and soluble guanylate cyclase and phosphodiester-
ase 5 protein levels (Western blot analysis).
Results: Initiation of nitric oxide decreased left pulmonary vascular resistance by
26.2%, and withdrawal rapidly increased pulmonary vascular resistance by 77.8% (P
.05). Tissue cyclic guanosine monophosphate concentrations initially increased during
nitric oxide therapy but were not maintained during the 24-hour exposure. In addition,
cyclic guanosine monophosphate concentrations rapidly decreased after nitric oxide
withdrawal (P  .05). The  soluble guanylate cyclase (45.7%) and  soluble
guanylate cyclase (48.4%) protein levels decreased during nitric oxide therapy (P 
.05), whereas phosphodiesterase 5 proteins levels were unchanged.
Conclusions: These data suggest a role for decreased soluble guanylate cyclase and its
resulting decrease in cyclic guanosine monophosphate concentrations in the nonsus-
tained response to nitric oxide and the rebound pulmonary hypertension noted on its
acute withdrawal. Phosphodiesterase 5 inhibitors may be a useful adjunct therapy during
inhaled nitric oxide to preserve cyclic guanosine monophosphate levels and thereby
preserve nitric oxide responsiveness and prevent rebound pulmonary hypertension.
Exogenously administered inhaled nitric oxide (NO) is currently usedas an adjuvant therapy for a number of pulmonary hypertensivedisorders. In both animal and human studies, inhaled NO (5 to 80ppm) induces rapid and selective pulmonary vasodilation.1-4 Whenadministered into the airways in its gaseous form, NO diffuses intopulmonary vascular smooth muscle cells and activates soluble guan-
ylate cyclase (sGC), a heterodimer with 1 and 1 subunits that catalyzes the
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production of cyclic guanosine monophosphate (cGMP)
from guanosine-5'-triphosphate. Cyclic GMP induces vas-
cular smooth muscle relaxation through activation of a
cGMP-dependent protein kinase, although the exact mech-
anism remains unclear.5,6 Cyclic nucleotide phosphodies-
terases (PDEs) regulate intracellular levels of cGMP by
catalyzing cGMP to GMP.7 PDE 5 is the predominant
cGMP-metabolizing PDE of pulmonary tissues.8 Several
clinical trials have demonstrated that inhaled NO improves
oxygenation and decreases the need for extracorporeal life
support in neonates with persistent pulmonary hyperten-
sion.2,3 In addition, nonrandomized studies demonstrate that
inhaled NO selectively decreases pulmonary arterial pres-
sure and pulmonary vascular resistance in patients with
perioperative pulmonary hypertension and decreases pul-
monary vascular resistance and improves oxygenation in
patients with acute lung injury.1,4
Although these data are encouraging, nonsustained re-
sponsiveness is common, and concerns regarding the safety
of inhaled NO therapy remain. For example, in acute lung
injury, inhaled NO improves oxygenation on initiation, but
this effect is not sustained.9,10 In addition, several studies
have noted a potentially life-threatening increase in pulmo-
nary vascular resistance on acute withdrawal of inhaled
NO.11,12 This rebound pulmonary hypertension is mani-
fested by an increase in pulmonary vascular resistance,
compromised cardiac output, severe hypoxemia, or a com-
bination of these.11,12 Increasing data demonstrate that ex-
ogenous NO exposure inhibits endogenous endothelial NO
synthase (NOS) activity, suggesting that transient decreases
in endogenous NOS activity during inhaled NO therapy
may be a potential mechanism for rebound pulmonary hy-
pertension.13-15 Limited in vitro data suggest that exogenous
NO may directly alter sGC gene expression.16,17 However,
the potential effects of inhaled NO on pulmonary sGC and
PDE 5 signaling in vivo are unknown.
The purpose of this study was to investigate the effects of
inhaled NO endogenous sGC and PDE 5 protein levels in
the intact lamb. To this end, inhaled NO (40 ppm) was
administered to 7 intact 1-month-old lambs for 24 hours and
then acutely withdrawn. Sequential blood was taken for
plasma cGMP determinations, and sequential peripheral
lung biopsy samples were taken for tissue cGMP determi-
nations and protein level determinations of sGC and PDE 5
by Western blot analysis. Four additional lambs underwent
an identical protocol without inhaled NO therapy.
Methods
Surgical Preparation
Eleven lambs (30.1  4.3 days old) were fasted for 24 hours, with
free access to water. The lambs were then anesthetized with
ketamine hydrochloride (15 mg/kg intramuscularly). With lambs
under additional local anesthesia with 1% lidocaine hydrochloride,
polyurethane catheters were placed in an artery and vein of a hind
leg. These catheters were advanced to the descending aorta and the
inferior vena cava, respectively. The lambs were then anesthetized
with ketamine hydrochloride (approximately 0.3 mg · kg1 ·
min1), diazepam (0.002 mg · kg1 · min1), and fentanyl citrate
(1.0 g · kg1 · h1), intubated with a 7.0-mm-outer-diameter
cuffed endotracheal tube, and mechanically ventilated with a
Healthdyne pediatric time-cycled, pressure-limited ventilator. Pan-
curonium bromide (0.1 mg/kg per dose) was given intermittently
for muscle relaxation. By using strict aseptic technique, a midster-
notomy incision was then performed, and the pericardium was
incised. By using a purse-string suture technique, polyurethane
catheters were placed directly into the right and left atrium and the
main pulmonary artery. An ultrasonic flow probe (Transonics
Systems, Ithaca, NY) was placed around the left pulmonary artery
to measure pulmonary blood flow. The midsternotomy incision
was then temporarily closed with towel clamps. An intravenous
infusion of Ringer’s lactate and 5% dextrose (75 mL/h) was begun
and continued throughout the study period. Cefazolin (500 mg IV)
and gentamicin (3 mg/kg IV) were administered before the first
surgical incision and every 8 hours thereafter. The lambs were
maintained normothermic (39°C) with a heating blanket.
Experimental Protocol
After a 30-minute recovery, baseline measurements of the hemo-
dynamic variables (pulmonary and systemic arterial pressure, heart
rate, left pulmonary blood flow, and left and right atrial pressures),
systemic arterial blood gases, and pH were measured (before NO).
Blood was obtained for plasma cGMP determinations, and periph-
eral lung wedge biopsy samples were obtained for tissue cGMP
determinations and sGC and PDE 5 protein determinations. A
side-biting vascular clamp was used to isolate peripheral lung
tissue from a randomly selected lobe, and the incision was cauter-
ized. Approximately 300 mg of peripheral lung was obtained for
each biopsy sample.
In 7 of the lambs, inhaled NO (40 ppm) was then delivered in
nitrogen into the inspiratory limb of the ventilator (Inovent; Ohm-
eda Inc, Liberty, NJ) and continued for 24 hours. The inspired
concentrations of NO and nitrogen dioxide were continuously
quantified by electrochemical methodology (Inovent). The hemo-
dynamic variables were monitored continuously. Systemic arterial
blood gases were determined intermittently, and ventilation was
adjusted to achieve a PaCO2 between 32 and 45 mm Hg and a PaO2
greater than 50 mm Hg. Sodium bicarbonate was administered
intermittently to maintain a pH greater than 7.30. Normal saline
was administered intermittently to maintain stable atrial pressures
throughout the study period. Peripheral lung wedge biopsies were
performed after 2, 6, and 24 hours of therapy. The inhaled NO was
then stopped, and the hemodynamic variables were monitored for
2 additional hours. To ensure that the potential changes demon-
strated resulted from inhaled NO and not from mechanical venti-
lation alone, 4 lambs were mechanically ventilated for 24 hours, as
described previously, without inhaled NO therapy.
At the end of the protocol, all lambs were killed with a lethal
injection of sodium pentobarbital followed by bilateral thoracot-
omy as described in the National Institutes of Health Guide for the
Care and Use of Laboratory Animals. All protocols and proce-
dures were approved by the Committee on Animal Research of the
University of California, San Francisco. All animals received
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humane care in compliance with the Guide for the Care and Use
of Laboratory Animals.
Measurements
Pulmonary and systemic arterial and right and left atrial pressures
were measured with Sorenson Neonatal Transducers (Abbott Crit-
ical Care Systems, North Chicago, Ill). Mean pressures were
obtained by electrical integration. Heart rate was measured by a
cardiotachometer triggered from the phasic systemic arterial pres-
sure pulse wave. Left pulmonary blood flow was measured on an
ultrasonic flow meter (Transonic Systems). All hemodynamic vari-
ables were recorded continuously on a Gould multichannel elec-
trostatic recorder (Gould Inc, Cleveland, Ohio). Systemic arterial
blood gases and pH were measured on a Radiometer ABL5 pH/
blood gas analyzer (Radiometer, Copenhagen, Denmark). Hemo-
globin concentration and oxygen saturation were measured by a
hemoximeter (model 270, Ciba-Corning, East Walpole, Mass).
Pulmonary vascular resistance was calculated by using standard
formulas. Body temperature was monitored continuously with a
rectal temperature probe.
Cyclic GMP Determinations
Blood samples (1-2 mL) were collected in iced Vacutainer tubes
(Becton Dickinson, Franklin Lakes, NJ) containing ethylenedia-
minetetraacetic acid (7.5 mmol/L). The samples were centrifuged
(4000g for 15 minutes), and the resulting plasma was stored in
polypropylene storage tubes at 70°C. At the time of the assay,
the plasma (200 L) was diluted 1:1 with 0.2 mol/L HCL and
vortexed, and the acidified plasma was passed through a 0.2-m
Centrex filter (Schleicher & Schuell Inc, Keene, NH) by centrif-
ugation (4000g for 15 minutes). Tissue was homogenized in 6%
trichloroacetic acid at 4°C to give a 10% wt/vol homogenate and
centrifuged at 2000 revolutions per minute for 15 minutes at 4°C.
The supernatant was recovered and washed 4 times with 5 volumes
of water-saturated diethyl ether. Aqueous extracts were then ly-
ophilized, and the dried pellet was resuspended in assay buffer
before analysis. The samples were assayed with a cGMP (iodine
125) radioimmunoassay kit (Amersham International, Amersham,
UK) according to the manufacturer’s instructions. Cross-reactivity
for other nucleotides was less than 0.001.
Western Blot Analysis
Western blot analysis was performed as previously described.18
Protein extracts prepared from lung biopsy samples (100 g) were
separated on 10% sodium dodecyl sulfate-polyacrylamide gel and
electrophoretically transferred to Hybond polyvinylidene difluo-
ride membranes (Amersham, Arlington Heights, IL). The mem-
branes were blocked with 5% nonfat dry milk in Tris-buffered
saline containing 0.1% Tween. After blocking, the membranes
were incubated at room temperature with the appropriate dilution
of the antiserum of interest (1:1000 for the 1 subunit of guanylate
cyclase, 1:10,000 for the 1 subunit of guanylate cyclase [antisera
for the 1 subunit and the 1 subunit of guanylate cyclase were a
gift from Peter Yuen, PhD], or 1:2000 for PDE 5 [a gift from Dr
Stefan Janssens, University Hospital Gasthuisberg, Lueven, Bel-
gium]), washed with Tris-buffered saline containing 0.1% Tween,
and then incubated with the appropriate species of anti–immuno-
globulin G horseradish peroxidase conjugate. After washing,
chemiluminescence (Pierce Laboratories, Rockford, Ill) was used
to detect the protein bands of interest. Quantitation of autoradio-
graphic results was performed by scanning (Hewlett-Packard SCA
Jet IICX; Hewlett-Packard Inc, Palo Alto, Calif) the bands of
interest into an image-editing software program (Adobe Photo-
shop; Adobe Systems, Mountain View, Calif). Band intensities
from Western blot analysis were analyzed densitometrically on a
Macintosh computer (model 9500; Apple Computer, Inc, Cuper-
tino, Calif) by using the public-domain NIH Image program (de-
veloped at the National Institutes of Health and available on the
Internet at http://rsb.info.nih.gov/nih-image). For Western blot
analysis, to ensure equal protein loading, duplicate polyacrylamide
gels were run. One was stained with Coomassie blue.
Statistical Analysis
The mean  SE was calculated for the baseline hemodynamic
variables, systemic arterial blood gases, pH, and cGMP concen-
trations. Comparisons over time were made by analysis of variance
for repeated measures. The mean  SE was calculated for the
relative protein of interest from pre- and post-NO lungs. Results
from pre-NO lungs were assigned the value of 1 (relative protein
of interest). Comparisons were made by the paired t test.
Results
Inhaled NO (40 ppm) transiently decreased mean pulmo-
nary arterial pressure and left pulmonary vascular resistance
(from to 0.242  0.04 to 0.179  0.02 mm Hg/mL per
minute per kilogram; P  .05; Table 1, Figure 1). Left
pulmonary blood flow, mean systemic arterial pressure,
heart rate, right and left atrial pressures, systemic arterial
blood gases, and pH were all unchanged. During the 24-
hour treatment course, pulmonary arterial pressure returned
to the pre-NO value. Systemic arterial pressure slightly
decreased and systemic arterial PCO2 increased in compari-
son to pre-NO values (Table 1). On discontinuation of
inhaled NO, there was a rapid increase in both mean pul-
Figure 1. Changes in left pulmonary vascular resistance before,
during, and after 24 hours of inhaled nitric oxide (40 ppm) therapy;
n  7 lambs. Values are mean  SEM. *P < .05 versus 0 hours;
†P < .05 versus previous data point (analysis of variance).
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monary arterial pressure and left pulmonary vascular resis-
tance (P  .05; Table 1, Figure 1). Right atrial pressure
increased, and systemic arterial PO2 decreased (P  .05).
Left pulmonary blood flow, mean systemic arterial pressure,
heart rate, left atrial pressures, systemic arterial PCO2, and
pH remained unchanged from 24-hour NO values (Table 1).
Ventilation alone, without inhaled NO, did not change mean
pulmonary arterial pressure, pulmonary blood flow, pulmo-
nary vascular resistance, left and right atrial pressures, heart
rate, systemic arterial blood gases, or pH. Mean systemic
arterial pressure decreased slightly from 71.8  11.1 mm
Hg to 61.0  7.4 mm Hg (P  .05).
To determine the effects of inhaled NO on endogenous
cGMP production, we determined plasma and lung tissue
cGMP concentrations. We found that plasma cGMP con-
centrations increased on initiation of inhaled NO and re-
mained increased during the 24-hour treatment period (P 
.05). Withdrawal of NO was associated with a decrease in
cGMP concentrations, which remained decreased 2 hours
after discontinuation (Figure 2). Similarly, lung tissue con-
centrations of cGMP increased on initiation of inhaled NO
(P  .05). However, this increase was not sustained during
the 24-hour treatment period. Withdrawal of NO was also
associated with a rapid decrease in tissue cGMP levels,
which remained below baseline values during the 2-hour
observation period (P  .05; Figure 3).
Inhaled NO therapy decreased protein levels of both the
1 subunit of sGC and the 1 subunit of sGC (P  .05;
Figures 4 and 5). However, ventilation alone, without in-
haled NO, did not change protein levels (Figures 4 and 5).
PDE 5 protein levels were not changed during inhaled NO
(Figure 6).
Discussion
Although many studies demonstrate a clear benefit in pa-
tient outcome with inhaled NO use, several safety concerns
remain, including its potential acute and chronic adverse
effects on endogenous endothelial function.1-4,9-12 For ex-
ample, recent in vitro and in vivo data suggest that exoge-
nous NO decreases endogenous NOS activity.13,14 How-
ever, the potential effects of inhaled NO on downstream
mediators of the NO-cGMP cascade had not been investi-
TABLE 1. The hemodynamic changes during and after 24 hours of inhaled NO
Variable Before NO
Inhaled NO (40 ppm) Off NO
15 min 2 h 6 h 24 h 10 min off 30 min off 60 min off 120 min off
Pulmonary
arterial
pressure
(mm Hg)
13.2 1.3 11.6 1.8*† 12.9 2.7 12.0 2.0 12.0 1.2 16.8 0.6*† 17.2 1.6* 17.1 1.6* 16.4 2.1*
Left
pulmonary
blood flow
(mL · kg1
· min1)
33.3 7.3 33.8 6.9 33.7 6.5 33.2 9.8 29.1 6.1 28.1 5.4* 31.8 4.3 30.5 3.3 31.1 4.4
Systemic
arterial
pressure
(mm Hg)
63.7 6.9 61.7 9.5 62.9 10.4 60.2 10.7 45.7 6.9*† 48.9 15.3* 49.1 10.7* 48.3 9.2* 48.2 13.8*
Heart rate
(beats/
min)
152.0 17.7 142.7 14.1 146.4 16.4 144.0 16.5 137.9 17.5 135.9 12.6* 144.8 21.2 143.8 21.5 143.9 18.6
Left atrial
pressure
(mm Hg)
5.1 1.9 5.6 2.0 5.1 2.3 4.1 1.1 5.7 0.5 6.0 1.7 5.5 1.5 5.3 1.9 4.7 1.4
Right atrial
pressure
(mm Hg)
4.2 1.7 4.0 1.5 4.0 1.4 3.0 1.2 4.0 1.9 5.7 2.1*† 5.1 1.6 5.0 1.5 4.7 1.3
pH 7.41 0.03 7.42 0.03 7.44 0.02* 7.41 0.02 7.39 0.05 7.38 0.03 7.36 0.03* 7.38 0.04 7.37 0.03
PaCO2 (mm
Hg)
33.1 3.2 32.7 2.1 33.1 1.3 38.4 2.4*† 36.7 2.0* 37.7 3.7* 39.0 5.6* 37.7 4.7* 37.9 2.5*
PaO2 (mm
Hg)
77.4 6.1 86.4 6.4 84.7 7.6 73.7 5.7† 83.6 17.9† 61.6 7.0*† 60.7 4.8 59.6 4.7 57.6 6.4*
NO, Nitric oxide. Values are mean  SD; n  7.
*P  .05 versus before NO.
†P  .05 versus previous column (analysis of variance).
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gated. To our knowledge, this study is the first in vivo
investigation of the effects of exogenous inhaled NO ther-
apy on endogenous sGC and PDE 5 protein expression.
Using a sequential lung biopsy technique in the intact
1-month-old lamb, we found that inhaled NO decreases
lung tissue sGC protein levels by approximately 50%,
whereas PDE 5 levels are unchanged. These net alterations
result in decreased endogenous pulmonary cGMP produc-
tion during and after inhaled NO withdrawal.
Soluble GC is a heterodimeric enzyme composed of 2
subunits, termed  and , that generates cGMP from
guanosine 5 triphosphate.19 Although much focus has been
placed on potential alterations in NOS expression in pul-
monary hypertensive disorders, data also suggest that po-
tential changes in sGC expression and activity may be
important in the pathophysiology of pulmonary hyperten-
sion.20-22 For example, decreased sGC protein levels and
activity have been demonstrated in animal models of per-
sistent pulmonary hypertension of the neonate.21,22 In vitro,
this is associated with impairment in the pulmonary vaso-
dilating response to NO donors and may play a role in the
decreased responsiveness of some neonates with persistent
pulmonary hypertension of the neonate.21,22 Decreases in
sGC gene expression and activity have also been implicated
in other vascular disorders, including essential hyperten-
sion.23 Although few data are available on the regulation of
sGC, limited in vitro studies suggest that exogenous NO
does alter sGC expression and activity. For example, in rat
medullary interstitial cells, NO-donor compounds decreased
the messenger RNA levels of both 1 and 1 sGC sub-
units.16 In addition, in rat pulmonary artery smooth muscle
cells, exposure to NO donors induced a cGMP-dependent
decrease in sGC messenger RNA and protein levels.17 This
study is the first in vivo demonstration that inhaled NO
decreases pulmonary 1 and 1 sGC protein levels. We
speculate that this effect is mediated by a direct effect of
exogenous NO exposure, as demonstrated in pulmonary
vascular smooth muscle cells.17 However, in the kidney,
endogenous NOS inhibition has been demonstrated to de-
crease sGC activity.24 Therefore, a potential secondary ef-
fect of the decreased endogenous NOS activity, which oc-
curs during NO exposure, on sGC cannot be excluded.13,14
These and other potential mechanisms require further study.
Intracellular cGMP concentrations are not determined
simply by the accumulation of cGMP, but rather by a
balance between synthesis and degradation. Cyclic nucleo-
tide PDEs are the enzymes responsible for cGMP degrada-
tion.7 In the mammalian lung, there are a number of PDEs,
but the cGMP-specific PDE, PDE 5, is prevalent, especially
early in development.8 In this study we have demonstrated
that the expression of PDE 5 is unchanged during inhaled
NO therapy. As with sGC, little is known about the regu-
lation of PDE 5 gene expression. However, developmental
regulation and alterations in animal models of pulmonary
hypertension have been demonstrated.8,25
Previous in vivo and in vitro data demonstrate that in-
haled NO decreases endogenous NOS activity via an endo-
thelin-1–dependent process, suggesting that decreased en-
dogenous NOS activity mediates, at least in part, the
rebound pulmonary hypertension associated with with-
drawal of inhaled NO therapy.13,14,26,27 In this study, inde-
pendent of changes in NOS, the net effect of decreased sGC
without a compensatory decrease in PDE 5 may result in
decreased cGMP production. This may explain why the
initial increase in tissue cGMP concentrations during in-
haled NO therapy did not persist throughout the entire
24-hour treatment period (Figure 3) and is a potential eti-
ology for nonsustained NO responses demonstrated in hu-
man trials.9,10 Similarly, on withdrawal of exogenous NO,
basal cGMP production will be decreased and may contrib-
Figure 3. Changes in lung tissue cGMP concentrations before,
during, and after 24 hours of inhaled NO (40 ppm) therapy; n  6.
Values are mean  SEM. *P < .05 versus before NO (Pre NO).
Figure 2. Changes in plasma cGMP concentrations before, dur-
ing, and after 24 hours of inhaled NO (40 ppm) therapy; n  6.
Values are mean  SEM. *P < .05 versus before NO (Pre NO).
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Figure 4. Western blot analysis for the 1 subunit of soluble guanylate cyclase protein in lung tissue before and
after 24 hours of inhaled nitric oxide (40 ppm) therapy. A, A representative Western blot is shown from protein
extracts (100 g) prepared from lung tissue before and after NO therapy, separated on a 10% sodium dodecyl
sulfate-polyacrylamide gel, electrophoretically transferred to Hybond membranes, and analyzed with a specific
antiserum raised against the 1 subunit of soluble guanylate cyclase (1 sGC) protein. The sGC 1 protein
expression was decreased during NO therapy. B, The densitometric values for relative 1 sGC protein (normalized
to before NO [Pre]) from 5 lambs. Values are mean  SEM. The 1 sGC protein expression was decreased during
inhaled NO therapy. C, Representative Western blot of ventilation alone, without NO. The 1 sGC protein
expression was unchanged during ventilation alone.
Figure 5. Western blot analysis for the 1 subunit of soluble guanylate cyclase protein in lung tissue before and
after 24 hours of inhaled nitric oxide (40 ppm) therapy. A, A representative Western blot is shown from protein
extracts (100 g) prepared from lung tissue before and after NO therapy, separated on a 10% sodium dodecyl
sulfate-polyacrylamide gel, electrophoretically transferred to Hybond membranes, and analyzed with a specific
antiserum raised against the 1 subunit of soluble guanylate cyclase protein. The 1 sGC protein expression was
increased during inhaled NO therapy. B, The densitometric values for the 1 subunit of soluble guanylate cyclase
protein (normalized to before NO [Pre]) from 5 lambs. Values are mean  SEM. The 1 sGC protein expression was
increased during inhaled NO therapy. C, Representative Western blot of ventilation alone, without NO. The 1 sGC
protein expression was unchanged during ventilation alone.
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ute to the physiologic increase in pulmonary vascular resis-
tance noted on NO withdrawal.
It is interesting to note that changes in plasma cGMP
levels did not completely track with lung tissue cGMP
levels (Figures 2 and 3). Similar to tissue levels, plasma
levels increased on initiation of inhaled NO. However,
unlike tissue levels, plasma cGMP levels remained in-
creased throughout the 24-hour NO therapy and decreased
only after NO was discontinued. Cyclic GMP production is
the result of 2 major sources: activation of sGC via NO and
activation of particulate guanylate cyclase via natriuretic
peptides.28 Plasma cGMP levels reflect pulmonary and sys-
temic vascular NO production, nonvascular NO production,
and natriuretic peptide production, of which the myocar-
dium is a major source. Lung tissue cGMP levels predom-
inantly reflect vascular and nonvascular pulmonary NO
production. Therefore, changes in tissue cGMP are more
likely to reflect changes in endogenous pulmonary NO and
subsequent cGMP production, whereas plasma levels are
likely to be altered by other compensatory factors, such as
changes in natriuretic peptide production. Although poten-
tial alterations in natriuretic peptide production and other
nonpulmonary sources of cGMP during inhaled NO are
unclear, the current data suggest potential changes that
warrant further investigation.
Several limitations of this study are noteworthy. First,
only 1 dose of inhaled NO (40 ppm) and 1 treatment
duration (24 hours) were studied. In addition, rapid with-
drawal of a high dose was used, as opposed to the slower
weaning strategy that is often used clinically. Further inves-
tigations are needed to determine the potential effects of
different doses, treatment durations, and weaning strategies
on endogenous sGC and PDE 5. Finally, these studies were
performed in lambs with normal pulmonary circulations.
Patients with pulmonary hypertension, who are currently
treated with inhaled NO, often have preexisting aberrations
in the NO-cGMP cascades.20 Further studies are warranted,
and ongoing, to determine the effects of inhaled NO in
abnormal pulmonary circulation.
This study is the first in vivo investigation of the effects
of inhaled NO therapy on endogenous sGC and PDE 5
expression. We found that exogenous inhaled NO induces a
significant decrease of sGC protein without a compensatory
decrease in PDE 5. These changes were associated with a
decrease in tissue cGMP concentrations during treatment.
These data, taken together with previous investigations on
NOS activity, suggest that decreased endogenous cGMP
production mediates, at least in part, the nonsustained re-
sponsiveness to NO and the rebound pulmonary hyperten-
sion associated with withdrawal of inhaled NO therapy.
Therefore, PDE 5 inhibitors may be useful co-therapies to
augment the vasodilatory effects of inhaled NO and facili-
tate its discontinuation. In fact, sildenafil, a selective PDE 5
inhibitor, has been shown in recent human studies to aug-
ment the effect of inhaled NO and facilitate its weaning.29,30
We speculate that a better understanding of the mechanism
by which inhaled NO alters endogenous endothelial func-
tion will continue to lead to strategies that maximize the
benefits of NO treatment while minimizing its toxicities,
particularly during chronic therapy. In addition, these mech-
anisms may have important general clinical implications for
a variety of both pulmonary and systemic vascular disor-
ders, which include sickle cell disease, coronary artery
disease, and nitrate tolerance.
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